A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
What is the purpose of this trial?
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
- Trial withYale Cancer Center
- Start Date02/24/2020
- End Date02/29/2024
- Last Updated07/15/2021
- Study HIC#2000026850